Tenecteplase: A Review of Its Pharmacology and Uses

Author(s): Jenna Forry, PharmD, BCPS, Alyssa Chappell, PharmD, BCPS

Contact Hours 1.00

CERP A 1.00

Pharmacology Hours 1.00

Expires Jun 01, 2026

Topics: Pharmacology

Member: Free
NonMember: $10.00

Added to Collection

Activity Summary

Required reading for all learners: Implicit Bias impacts patient outcomes

Many hospital systems are adding tenecteplase to the formulary or switching to tenecteplase as the thrombolytic of choice despite its lack of FDA approval for indications other than myocardial infarction.3-5 Institutions cite workflow advantages and potential cost savings with tenecteplase (the wholesale acquisition cost is $8071.39 per 50-mg vial of tenecteplase, as compared with $10 560.43 per 100-mg vial of alteplase).1,2 Therefore, it is imperative for all clinicians involved with the treatment of patients with myocardial infarction, ischemic stroke, or PE to understand the pharmacology, uses, and clinical evidence regarding tenecteplase.


  • Discuss the pharmacology of tenecteplase.
  • Identify the key differences in dosing and administration of thrombolytics
  • Analyze the available literature for tenecteplase's use in acute ischemic stroke, pulmonary embolism, and acute myocardial infarction.

Continuing Education Disclosure Statement

Successful Completion

Learners must attend/view/read the entire activity, read Implicit Bias impacts patient outcomes, and complete the associated evaluation to be awarded the contact hours or CERP. No partial credit will be awarded.


The American Association of Critical-Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Provider approved by the California Board of Registered Nursing, Provider number CEP 1036, for 1.00 contact hours.

Accreditation refers to recognition of continuing education only and does not imply AACN, ANCC, or CBRN approval or endorsement of any commercial products discussed or displayed in conjunction with this educational activity.


Any relevant relationship between an ineligible company and an individual with the ability to influence clinical content will be identified by the Nurse Planner within the activity. Any relevant relationship between an ineligible company and an individual with the ability to influence clinical content has been mitigated.

AACN programming meets the standards for most states that require mandatory continuing education contact hours for license and/or certification renewal. AACN recommends consulting with your state board of nursing or credentialing organization before submitting CE to fulfill continuing education requirements.

Refund Policy

Continuing Education Activities are nonrefundable.